BACKGROUND: Both age and race have been identified as independent predictors of breast cancer subtype but the association of age with subtype within each race is not well understood. This study assesses the association of age with the eight breast cancer subtypes as defined by ER/PR/HER2 among white, African-American, Hispanic, and Asian/Pacific Islander women. METHODS: This study included 69,358 women with primary invasive breast cancer. Logistic regression was used to assess the association of age with each of the ER/PR/HER2 subtypes for each race adjusted for socioeconomic status, stage, grade, and tumor size. RESULTS: The odds of African-American women having a triple-negative tumor were not statistically significantly increased for women under 46 when compared to the African-American women aged 46-69 (OR=0.96; 95% CI=0.80-1.16). A similar pattern was observed for the ER-/PR-/HER2+ subtype. Hispanic women under age 46 (OR=0.83; 95% CI=0.71-0.97) and over age 70 (OR=0.71; 95% CI=0.57-0.89) were less likely to have the ER-/PR-/HER2+ subtype. Asian/Pacific Islander women under age 46 also had reduced odds (OR=0.67; 95% CI=0.55-0.82) of the ER-/PR-/HER2+ subtype. CONCLUSIONS: The ER/PR/HER2 subtypes vary with age and differences in this variation depend on race. It is important to define breast cancer using the ER/PR/HER2 subtype and the significance of age and race should not be overlooked.
BACKGROUND: Both age and race have been identified as independent predictors of breast cancer subtype but the association of age with subtype within each race is not well understood. This study assesses the association of age with the eight breast cancer subtypes as defined by ER/PR/HER2 among white, African-American, Hispanic, and Asian/Pacific Islander women. METHODS: This study included 69,358 women with primary invasive breast cancer. Logistic regression was used to assess the association of age with each of the ER/PR/HER2 subtypes for each race adjusted for socioeconomic status, stage, grade, and tumor size. RESULTS: The odds of African-American women having a triple-negative tumor were not statistically significantly increased for women under 46 when compared to the African-American women aged 46-69 (OR=0.96; 95% CI=0.80-1.16). A similar pattern was observed for the ER-/PR-/HER2+ subtype. Hispanic women under age 46 (OR=0.83; 95% CI=0.71-0.97) and over age 70 (OR=0.71; 95% CI=0.57-0.89) were less likely to have the ER-/PR-/HER2+ subtype. Asian/Pacific Islander women under age 46 also had reduced odds (OR=0.67; 95% CI=0.55-0.82) of the ER-/PR-/HER2+ subtype. CONCLUSIONS: The ER/PR/HER2 subtypes vary with age and differences in this variation depend on race. It is important to define breast cancer using the ER/PR/HER2 subtype and the significance of age and race should not be overlooked.
Authors: Christina A Clarke; Theresa H M Keegan; Juan Yang; David J Press; Allison W Kurian; Anish H Patel; James V Lacey Journal: J Natl Cancer Inst Date: 2012-07-05 Impact factor: 13.506
Authors: Lynn Rosenberg; Deborah A Boggs; Lauren A Wise; Lucile L Adams-Campbell; Julie R Palmer Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-07-20 Impact factor: 4.254
Authors: Gertraud Maskarinec; Ian Pagano; Galina Lurie; Erin Bantum; Carolyn C Gotay; Brian F Issell Journal: J Womens Health (Larchmt) Date: 2011-01-31 Impact factor: 2.681
Authors: Katie M O'Brien; Stephen R Cole; Lawrence S Engel; Jeannette T Bensen; Charles Poole; Amy H Herring; Robert C Millikan Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-10-31 Impact factor: 4.254
Authors: Lisa M Hines; Betsy Risendal; Tim Byers; Sarah Mengshol; Jan Lowery; Meenakshi Singh Journal: J Womens Health (Larchmt) Date: 2011-07-01 Impact factor: 2.681
Authors: Katie M Marker; Valentina A Zavala; Tatiana Vidaurre; Paul C Lott; Jeannie Navarro Vásquez; Sandro Casavilca-Zambrano; Mónica Calderón; Julio E Abugattas; Henry L Gómez; Hugo A Fuentes; Ruddy Liendo Picoaga; Jose M Cotrina; Silvia P Neciosup; Carlos A Castañeda; Zaida Morante; Fernando Valencia; Javier Torres; Magdalena Echeverry; Mabel E Bohórquez; Guadalupe Polanco-Echeverry; Ana P Estrada-Florez; Silvia J Serrano-Gómez; Jenny A Carmona-Valencia; Isabel Alvarado-Cabrero; María Carolina Sanabria-Salas; Alejandro Velez; Jorge Donado; Sikai Song; Daniel Cherry; Lizeth I Tamayo; Scott Huntsman; Donglei Hu; Roberto Ruiz-Cordero; Ronald Balassanian; Elad Ziv; Jovanny Zabaleta; Luis Carvajal-Carmona; Laura Fejerman Journal: Cancer Res Date: 2020-04-03 Impact factor: 12.701
Authors: Lynn Rosenberg; Traci N Bethea; Emma Viscidi; Chi-Chen Hong; Melissa A Troester; Elisa V Bandera; Christopher A Haiman; Laurence N Kolonel; Andrew F Olshan; Christine B Ambrosone; Julie R Palmer Journal: J Natl Cancer Inst Date: 2015-11-26 Impact factor: 13.506
Authors: Melissa A Troester; Xuezheng Sun; Emma H Allott; Joseph Geradts; Stephanie M Cohen; Chiu-Kit Tse; Erin L Kirk; Leigh B Thorne; Michelle Mathews; Yan Li; Zhiyuan Hu; Whitney R Robinson; Katherine A Hoadley; Olufunmilayo I Olopade; Katherine E Reeder-Hayes; H Shelton Earp; Andrew F Olshan; Lisa A Carey; Charles M Perou Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: Jodie M Fleming; Tyler C Miller; Mariam Quinones; Zhen Xiao; Xia Xu; Matthew J Meyer; Erika Ginsburg; Timothy D Veenstra; Barbara K Vonderhaar Journal: BMC Med Date: 2010-05-21 Impact factor: 8.775